API | radretumab

radretumab Report issue

Biologics mAb ADC Experimental

AACT

Active Ingredient History

NOW

Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: No
Payload: 131-iodine
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

131i-l19sip | radretumab

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue